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proximately	 1	 in	 7	 exhibited	 a	 GH	 peak	 <9	μg/L	 during	 a	 GHRH‐arginine	 test.	
However,	none	of	the	patients	fulfilled	the	consensus	criteria	for	adult	GHD.
K E Y W O R D S
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1  | INTRODUC TION
Prader‐Willi	 syndrome	 (PWS)	 is	 a	 rare	 disorder	 resulting	 from	 the	








Some	 features	 of	 people	 with	 PWS	 resemble	 those	 seen	 in	
growth	hormone	deficiency	 (GHD),	 such	as	short	 stature	and	an	
abnormal	body	composition	with	a	low	lean	body	mass	(LBM)	and	
an	 increased	 fat	 mass	 (FM).	 Long‐term	 continuous	 growth	 hor‐
mone	 (GH)	 treatment	 in	children	with	PWS	 improves	body	com‐
position,	linear	growth,	physical	strength,	cognition	and	adaptive	











adults	 with	 PWS	 have	 investigated	 GHD	 in	 adults	 who	 were	 not	
treated	with	GH	during	childhood	and	the	prevalence	of	GHD	var‐
ied	dependent	on	the	diagnostic	test	and	the	chosen	cut‐off	points,	
which	 were	 or	 were	 not	 corrected	 for	 BMI.	 This	 study	 aimed	 to	






Inclusion	 criteria	 for	 the	 present	 study	 were	 (i)	 genetically	 con‐
firmed	 diagnosis	 of	 PWS	 by	 a	 positive	 methylation	 test,	 (ii)	 GH	
treatment	during	childhood	 for	at	 least	 two	years	and	 (iii)	having	
attained	 adult	 height,	 defined	 as	 a	 height	 velocity	 <0.5	cm	 per	
6	months	and	epiphyseal	closure	as	demonstrated	by	a	radiograph	
of	 the	 left	 hand	 and	wrist.	 Exclusion	 criteria	were	 (i)	medication	








They	were	 treated	with	 biosynthetic	GH	 (Pfizer	 Inc)	 during	 child‐
hood,	administered	subcutaneously	once	daily	at	bedtime	in	a	dose	















GHRH‐arginine	 stimulation	 test	 in	 41	 participants.	 Total	 fat	 mass	
(FM;	kg)	and	lean	body	mass	(LBM;	kg)	were	assessed.	All	scans	were	
made	on	the	same	machine,	with	daily	quality	assurance.	The	intra‐
assay	coefficient	of	variation	 (CV)	 for	 fat	 tissue	was	0.41%‐0.88%	
and	for	LBM	1.57%‐4.49%.22	FM	was	also	expressed	as	percentage	





fasting,	with	 the	patients	 recumbent.	After	 an	 indwelling	 catheter	











Statistical	 analyses	 were	 performed	with	 spss	 24.0	 (SPSS	 Inc).	 Data	
were	 expressed	 as	 median	 (IQR).	 The	 GH	 response	 to	 GHRH	 and	
arginine	 was	 assessed	 by	 the	 evaluation	 of	 the	 highest	 GH	 plasma	
     |  3DONZE Et al.






















apy	 (SSRT),	 and	 seven	 had	 spontaneous	 oestrogen	 or	 testosterone	
levels	within	the	normal	range.	The	remaining	24	subjects	were	consid‐
ered	hypogonadal,	but	were	not	receiving	SSRT	at	time	of	evaluation.
3.2 | GH response to GHRH-arginine test
Table	2	and	Figure	1	show	the	results	of	 the	GHRH‐arginine	tests	













between	males	 and	 females	 (P	=	0.41).	 There	was	 also	no	 signif‐
icant	difference	 in	GH	peak	between	hypogonadal	patients	who	
were	 not	 receiving	 SSRT	 and	patients	who	were	 receiving	 SSRT	
or	had	spontaneous	oestrogen	and	testosterone	levels	within	the	
normal	 range	 at	 the	 time	of	 the	GHRH‐arginine	 stimulation	 test	
(P	=	0.67).
3.3 | Correlation analyses
A	 higher	 BMI	 SDS	 and	 a	 higher	 FM%	 SDS	 were	 significantly	 as‐




FM%	SDS	(r	=	−0.14,	P = 0.94 and r	=	0.008,	P	=	0.96,	resp.).
























TA B L E  1  Clinical	characteristics	at	
adult	height	and	during	childhood











in	 a	 large	 group	of	 60	 young	 adults	with	PWS,	who	were	 treated	
with	GH	for	more	than	10	years	during	childhood	until	attainment	









composition	 with	 an	 increased	 fat	 mass	 and	 decreased	 muscle	
mass.1	 Both	 children	 and	 adults	with	 PWS	 respond	 favourably	 to	
GH	treatment,	with	a	complete	normalization	of	stature	in	children,	
an	increase	in	serum	IGF‐I	and	IGFBP‐3	levels	and	a	significant	im‐








the	other	hand,	nine	 (15%)	patients	had	a	 low	GH	peak,	but	 com‐
pletely	normal	serum	IGF‐I	levels.
The	 reported	 prevalence	 of	 GHD	 in	 children	 and	 adults	 with	
PWS	varies.	According	 to	a	 review	by	Burman	et	al,12	40%‐100%	
of	 children	 with	 PWS	 fulfilled	 the	 criteria	 for	 GHD,	 depending	
on	 the	 stimulation	 test	 used.	 Three	 recent	 studies	 investigated	
the	 prevalence	 of	 GHD	 in	 mostly	 GH‐naïve	 adult	 PWS	 patients,	
aged	 16‐43	years,	 by	 performing	GHRH‐arginine	 tests.3,16,27 Two 




















TA B L E  2  GH	response	to	GHRH‐arginine	stimulation	test












     |  5DONZE Et al.
two	 studies.3,27	 Even	 though	BMI‐dependent	 cut‐off	 points	were	
used,	 a	 mean	 BMI	 of	 45.2	kg/m2	 is	 so	 far	 above	 the	 upper	 limit	












the	 appropriate	 cut‐off	 values	 for	GH	peak	during	GHRH‐arginine	
tests.	A	cut‐off	 value	of	15.9	μg/L	 for	 severe	adult	GHD	has	been	
proposed	for	retesting	late	adolescents	with	childhood‐onset	GHD.	
However,	due	to	the	small	number	of	overweight	patients,	a	separate	
cut‐off	 for	 adolescents	with	 a	high	BMI	was	not	obtained.30	One‐
third	of	our	patients	had	a	BMI	>25	kg/m2,	 and	 the	cut‐off	values,	
as	 proposed	 by	Dreismann	 et	 al,26	 are	 therefore	 not	 applicable	 to	
our	patients	with	PWS.	We	decided	to	use	the	BMI‐adjusted	adult	
cut‐off	values	instead.
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